688331 RemeGen Co., Ltd.
- 49.29
- -0.93-1.85%
RemeGen Co., Ltd. News
[Broker Focus] BOC International is optimistic about the recovery trend of overall investment sentiment in the pharmaceutical industry in 2Q/2H
Jinwu Financial News | BOC International said that recently, the US announced an increase in taxes on low-value consumables such as syringes, ranging from 0% to 50%. Considering that the gross margin of low-value consumables is generally low, the bank believes that a drastic tax increase will reduce the competitiveness of some Chinese products exported to the US market. In terms of sector allocation ideas, the bank is optimistic about the recovery trend of overall investment sentiment in the pharmaceutical industry in 2Q/2H, but the segment may continue to diverge. It is recommended to focus on leaders in major fields such as weight loss/NASH, medical equipment updates, pharmaceutical device innovation going overseas (new technology path/platform), reading significant data on innovative drugs, state-owned enterprise reform+high dividends
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant progress ...
RemeGen Celebrates World Lupus Day 2024 With Increased Lupus Visibility Through Vital Knowledge Sharing
The biotech company continues to offer hope to systemic lupus erythematosus (SLE) patients globally by sharing the latest developments of its proprietary novel fusion protein drug Telitacicept YANTAI
Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 5%, strong product sales in the first quarter, and an important catalyst is about to land
Rongchang Biotech (09995) rose more than 5%. As of press release, it rose 5.43% to HK$32.05, with a turnover of HK$24.2386 million.
BOC International: Maintaining Rongchang Biotech's “Buy” Rating Target Price of HK$56
BOC International released a research report stating that it maintains Rongchang Biotech's (09995) “buy” rating, with a target price of HK$56. The bank kept the company's profit forecast unchanged: revenue for 2024-26 reached 1.66 billion/2.50 billion/3.73 billion yuan respectively, net loss gradually narrowed, and break-even was achieved in 2027. The company has many catalysts in product commercialization, clinical data reading, mainland supervision and approval, and overseas travel in 2024. According to the report, the company's 1Q24 product sales continued to climb, reducing losses from month to month: according to A shares (688331.SH) disclosure, the company 1Q24
[Hong Kong Stock Connect] Rongchang Biotech (09995) rose 3.45%, institutions say it has impressive clinical research data
Jinwu Financial News | Rongchang Biotech (09995) continued to rise. As of press release, it reported HK$31.45, up 3.45%, with a turnover of HK$6.359 million. According to the news, BOC International stated that it will keep the company's profit forecast unchanged: 2024-26E net loss will gradually narrow, and break-even will be achieved in 2027. In 2024, the company had many catalysts in product commercialization, clinical data reading, domestic regulatory approval, overseas travel, etc., and the bank maintained a purchase rating and target price of HK$56. Previously, Sino-Thai International covered it for the first time and gave it a “buy” rating. It indicates that it is the first for domestic self-preventation+cancer
[Broker Focus] BOC International maintains Rongchang Biotech (09995) purchase rating, indicating that it has plenty of catalysts this year
Jinwu Financial News | According to the Bank of Commerce International Development Report, according to A-share disclosure, Rongchang Biotech (09995) recorded revenue of 330 million yuan in 1Q24, a year-on-year increase of 96.4%, and an increase of 5.4% over 4Q23. Among them, Tetasip and Verdicitol sold 170 million yuan and 160 million yuan respectively. Non-net loss of 350 million yuan was deducted in 1Q24, which was significantly narrower than 480 million yuan in 4Q23. Looking ahead to 2024, management will maintain the guideline of revenue growth of at least 50%, while R&D and sales expenses will be further reduced, and the annual capital requirement will be about 15-20 billion yuan. This line refers to the recommended key points
[Broker Focus] Zhongtai Securities first gave Rongchang Biotech (09995) a “buy” rating indicating that it has the ability to complete the entire chain from R&D to commercialization
Jinwu Financial News | According to the Zhongtai Securities Research Report, Rongchang Biotech (09995), as a pioneer in self-immunization+ cancer in China, has the ability to complete the entire chain of R&D to commercialization, and is promoting many clinical studies overseas. Two products have been marketed, and impressive data have been found in multiple clinical studies. According to the bank, verdicitumab is a HER2ADC that was approved for marketing earlier. It is promoting clinical research on new indications for different segments of the population in the fields of dominant gastric cancer and urothelial cancer. The bank believes that the revenue of verdicitril in 2024-2026 was 7.6/8.5/1.17 billion yuan, respectively. Tetracip as SLE's
Changes in Hong Kong stocks | Rongchang Biotech (09995) fell more than 7%, and the loss in the first quarter increased to 349 million yuan year-on-year, and previously announced a planned increase of 2.55 billion yuan
Rongchang Biotech (09995) fell by more than 7%. As of press release, it was down 7.54% to HK$28.2, with a turnover of HK$483.39 million.
Great Week for RemeGen Co., Ltd. (HKG:9995) Institutional Investors After Losing 33% Over the Previous Year
Key Insights Given the large stake in the stock by institutions, RemeGen's stock price might be vulnerable to their trading decisions The top 8 shareholders own 51% of the company 12% of RemeGen
榮昌生物：2024年第一季度報告
Rongchang Biotech (688331.SH) announced first-quarter results with a net loss of 349 million yuan
Rongchang Biotech (688331.SH) disclosed its report for the first quarter of 2024. The company achieved operating income during the reporting period...
榮昌生物：2023 年度報告
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 4%, and the company plans to increase nearly 2.6 billion yuan. The agency says there are many catalysts this year
Rongchang Biotech (09995) rose more than 4%. As of press release, it rose 4.76% to HK$29.7, with a turnover of HK$126.792 million.
Lu Tai A (000726.SZ): Currently holds about 3.91 million shares of Rongchang Biotech, and there are no plans to reduce its holdings
Gelonghui, April 17 | Lu Tai A (000726.SZ) said on the investor interactive platform that the company currently holds about 3.91 million shares of Rongchang Biotech and has no plans to reduce its holdings. The fund jointly set up by the company and Haojun Investment has an investment of about 50 million yuan.
Rongchang Biotech (09995.HK) plans to hold a board meeting on April 26 to approve the first quarter results
Gelonghui, April 16, 丨 Rongchang Biotech (09995.HK) announced that the company will hold a board meeting on April 26, 2024 (Friday) to consider and approve (among other things) the unaudited first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their publication.
榮昌生物：董事會召開日期
How many difficulties are there on the way to the Rongchang Biotech Plan's fixed increase of over 2 billion yuan
“Investor Network” Cai Jun Rongchang Biotech (688331.sh, hereinafter referred to as the “Company”) has reached another critical point. At the end of March, the company announced a fixed increase plan. It plans to raise up to 2.55 billion yuan, all of which will be used for “new drug research and development projects”, including RC18, RC48, RC28, RC88, RC148, and RC198. Around the same time, the company also released its 2023 annual report. Up to now, the company's core marketed products include taitacip, verdicitumab, etc. During the reporting period, the company's revenue increased by 40.26% year on year, net profit to mother - 1.51 billion yuan, loss
Analysis
Price Target
No Data
